Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

被引:0
|
作者
Almulhem, Maryam [1 ,2 ]
Ward, Christopher [1 ]
Haq, Iram [1 ,3 ]
Gray, Robert D. [4 ]
Brodlie, Malcolm [1 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[2] King Faisal Univ, Coll Appl Med Sci, Al Hasa, Saudi Arabia
[3] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Resp Med, Newcastle Upon Tyne, England
[4] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland
关键词
pulmonary exacerbation; cystic fibrosis; definition; QUALITY-OF-LIFE; CHILDREN; ADULTS; TRIAL; AZITHROMYCIN; RATIONALE; FREQUENCY; OUTCOMES; DESIGN; FEV1;
D O I
10.1136/bmjresp-2024-002456
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them.Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis.Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis.Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Risk factors leading to pulmonary exacerbation in patients with cystic fibrosis: A systematic review
    Aziz, Danish Abdul
    Fatima, Syeda Khadija
    Tahir, Hasan Nawaz
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2021, 71 (09) : 2217 - 2223
  • [2] Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
    Sanders, Don B.
    Bittner, Rachel C. L.
    Rosenfeld, Margaret
    Hoffman, Lucas R.
    Redding, Gregory J.
    Goss, Christopher H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (05) : 627 - 632
  • [3] Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis
    Woodley, Frederick W.
    Gecili, Emrah
    Szczesniak, Rhonda D.
    Shrestha, Chandra L.
    Nemastil, Christopher J.
    Kopp, Benjamin T.
    Hayes, Don, Jr.
    RESPIRATORY MEDICINE, 2022, 191
  • [4] Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation
    Hassanzad, Maryam
    Kiani, Arda
    Abedini, Atefeh
    Ghaffaripour, Hoseinali
    Emami, Habib
    Alizadeh, Niloufar
    Zoghi, Ghazal
    Hashemi, Saeed
    Velayati, Ali Akbar
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [5] Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionals
    McCourt, Fiona
    O'Neill, Brenda
    Logan, Ian
    Abbott, Janice
    Plant, Barry
    McCrum-Gardner, Evie
    McKeown, Stephanie
    Elbom, J. Stuart
    Bradley, Judy M.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (01) : 90 - 96
  • [6] Predictors of pulmonary exacerbation treatment in cystic fibrosis
    Sanders, Don B.
    Ostrenga, Joshua S.
    Rosenfeld, Margaret
    Fink, Aliza K.
    Schechter, Michael S.
    Sawicki, Gregory S.
    Flume, Patrick A.
    Morgan, Wayne J.
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (03) : 407 - 414
  • [7] Defining an exacerbation of pulmonary disease in cystic fibrosis
    Dakin, C
    Henry, RL
    Field, P
    Morton, J
    PEDIATRIC PULMONOLOGY, 2001, 31 (06) : 436 - 442
  • [8] Home Intravenous Antibiotic Protocols for Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis: A Scoping Review
    Odendaal, Michelle
    Tilbury, Zak
    Conway, Aaron
    HOME HEALTH CARE MANAGEMENT AND PRACTICE, 2025,
  • [9] Telerehabilitation in Children and Adolescents with Cystic Fibrosis: A Scoping Review
    Pessoa, Ezequiel
    Ferreira, Mara
    Baixinho, Cristina Lavareda
    HEALTHCARE, 2024, 12 (10)
  • [10] A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis
    Reeves, Emer P.
    Bergin, David A.
    Fitzgerald, Sean
    Hayes, Elaine
    Keenan, Joanne
    Henry, Michael
    Meleady, Paula
    Vega-Carrascal, Isabel
    Murray, Michelle A.
    Low, Teck Boon
    McCarthy, Cormac
    O'Brien, Emmet
    Clynes, Martin
    Gunaratnam, Cedric
    McElvaney, Noel G.
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (02) : 100 - 107